Escherichia coli (E. coli) is a bacterial bacilli known to be negative for the gram dye, and it is part of the normal flora inside the human body. The current study was designed to investigate the possibility of using LPS as an antimicrobial agent. 30 isolates of E.coli were collected from100 specimens of urine isolated from recurrent –urinary tract infections (UTI) patients they came to Al-Sadr Teaching Hospital. The samples were cultured on identification media, then diagnosed according to the phenotypic form and biochemical tests, and finally by VITK-2. The results of the prevalence of E. coli isolates showed that from 30 isolates of E.coli which were collected from 100 urine specimens 14 (46.6%), 6 (20%) and 10 (33.3%) were belong to the urinary tract infections, kidney stones and urinary catheter samples, respectively. The isolates showed multiple drug resistance (MDR) to most of the antibiotics used in the study. So, the lipopolysaccharide extracted from E. coli was used as an antimicrobial agent. The recorded data obtained from the PCR for WaaA, WaaC, wamB and wabG gene showed that the isolates were possessed biosynthesis genes for LPS. The results showed LPS at concentrations of 150, 250, and 500 μg /ml has as an anti-growth agent for Klebsiella pneumonia, Proteus mirabilis, Salmonella typhi, Pseudomonas aeruginosa, Bacillus subtilis, Staph aureus and candida albicans. Highest inhibitory effect was observed on K. pneumonia, P.mirabilis, S. typhi, B. subtilis and C. albicans compared to the control antimicrobials agents (Amoxicillin , Nystatin). LPS loaded on liposome nanoparticle can open new horizons in medicine by including it in the manufacture of broad-spectrum of antibiotics. |